X

RET+ NSCLC

RET+ NSCLC

Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions

The use of novel therapeutic drugs in lung cancer has changed the paradigm of the diagnosis and treatment of lung cancer.

Cancers
04/12/2021
The Fusion Gene Landscape in Taiwanese Patients With Non–Small-Cell Lung Cancer

Study investigators characterize the fusion gene landscape of NSCLC in a case study of Taiwanese lung cancer patients.

Cancers
03/16/2021
Therapeutic Strategies in RET Gene Rearranged Non-Small-Cell Lung Cancer

The results from the LIBRETTO-001 and ARROW clinical trials demonstrate significant clinical benefits with selpercatinib and pralsetinib respectively, in NSCLC patients with RET gene fusions...

Journal of Hematology & Oncology
03/26/2021

Integration of Comprehensive Genomic Profiling, Tumor Mutational Burden, and PD‐L1 Expression to Identify Novel Biomarkers of Immunotherapy in Non‐Small-Cell Lung Cancer

This study explores the novel biomarkers for immune checkpoint inhibitor responses in NSCLC by integrating genomic profiling, tumor mutational burden, and expression of PD‐L1.

Cancer medicine journal
03/02/2021
Combo Therapy May Target MET-Dependent Resistance in RET+ NSCLC

With the help of single patient protocols, researchers discover that combining selpercatinib with crizotinib targets MET-amplified resistance found in RET+ NSCLC treated with selpercatinib alone.

Oncology Learning Network
01/01/2021
Selpercatinib Shows Activity in RET Fusion–Positive NSCLC and RET-Altered Thyroid Cancer

The phase I/II LIBRETTO-001 trial has shown marked activity of the RET kinase inhibitor selpercatinib in patient cohorts with RET fusion–positive NSCLC and RET-altered thyroid can

The ASCO Post
11/10/2020
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing promising efficacy with a manageable toxicity profile.

OncoTargets and Therapy
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer

The aim of this review is to explore recent knowledge on RET resistance in NSCLC in pre-clinic and in clinical settings and accordingly, the state-of-the-art in new drugs or combination of drugs de

Cancers
03/04/2021
ESMO Recommendations on the Standard Methods to Detect RET Fusions and Mutations in Daily Practice and Clinical Research

New selective RET inhibitors have activity and favorable toxicity profiles in RET-altered solid tumors.

Annals of Oncology
03/01/2021
Phase III Study of Selpercatinib Versus Chemotherapy ± Pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer

Selpercatinib demonstrates clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion positive NSCLC patients in a Phase I/II clinical tr

Future Oncology
11/05/2020
FDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLC

The FDA  approved pralsetinib (Gavreto) for the treatment of adult patients with metastatic RET fusion–positive NSCLC, as detected by an FDA-approved test. 

The ASCO Post
09/08/2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39